

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

CHANGE OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board announces that with effect from 25 April 2025:

1. Ms Yu Xiaohui has been appointed as a non-executive Director and a member of the Audit Committee;
2. Mr Tao Ran has resigned as a non-executive Director and a member of the Audit Committee.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that with effect from 25 April 2025, Ms Yu Xiaohui (于曉輝) (“**Ms Yu**”) has been appointed as a non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”).

The biography of Ms Yu is set out below:

Ms Yu Xiaohui, aged 47, obtained her doctoral degree from the Institute of Zoology of Chinese Academy of Sciences (中國科學院動物研究所) in 2006. Ms Yu has extensive experience in pharmaceutical research and development management. She previously served as an assistant director of the Industrial Development and Scientific Research Management Department of China National Pharmaceutical Group Corporation (中國醫藥集團有限公司). She also was a director of the R&D Management Department at China Resources Pharmaceutical Group Limited (華潤醫藥集團有限公司). Currently, Ms. Yu serves as the deputy general manager (acting) of the R&D Management Department at China Resources Pharmaceutical Group Limited and as the Deputy General Manager (acting) of China National Pharmaceutical Research and Development Center Co., Ltd. (中國醫藥研究開發中心有限公司).

The term for the appointment of Ms Yu as a non-executive Director is three years and her appointment is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Ms Yu is not entitled to any Director's fee under her appointment letter.

Pursuant to the articles of association of the Company, Ms Yu shall hold office only until the first annual general meeting of the Company after her appointment where she shall be eligible for re-election. She shall be subject to retirement by rotation thereafter and shall then be eligible for re-election.

Save as disclosed above, as at the date of this announcement, Ms Yu confirmed that (i) she does not hold any position in the Company or any of its subsidiaries nor have any relationship with any Directors, senior management or substantial or controlling shareholders (having the meaning ascribed to it in the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**")) of the Company; (ii) she has not held other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) she does not have other major appointments and professional qualifications; (iv) she does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed under Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) there is no other information relating to her that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules or other matters that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") in connection with her appointment as a non-executive Director.

The Board would like to express its warmest welcome to Ms Yu for joining the Board.

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board further announces that Mr Tao Ran (陶然) ("**Mr Tao**") has resigned from his position as a non-executive Director and a member of the Audit Committee with effect from 25 April 2025, due to his other job arrangement. Mr Tao has confirmed that he has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr Tao for his valuable contribution to the Company during his tenure of service.

By order of the Board
Immunotech Biopharm Ltd
Tan Zheng
Chairman and executive Director

Hong Kong, 25 April 2025

As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu as executive Directors, Ms Yu Xiaohui, Mr Wang Ruihua, Mr Yang Fan and Mr Wang Donghu as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.